N-Acetyl Calicheamicin g1

Article number:

5600058

CAS-No.:

108212-76-6

Go to product

Nemorubicin

Article number:

5600025

CAS-No.:

108852-90-0

Go to product

Oleandrin

Article number:

5600067

CAS-No.:

465-16-7

Go to product

OSW-1

Article number:

5600082

CAS-No.:

145075-81-6

Go to product

PF-06380101

Article number:

5600080

CAS-No.:

1436391-86-4

Go to product

Phallacidin

Article number:

5600029

CAS-No.:

26645-35-2

Go to product

Phalloidin

Article number:

5600030

CAS-No.:

17466-45-4

Go to product

Phytosphingosine

Article number:

5600018

CAS-No.:

554-62-1

Go to product

PNU-159682

Article number:

5600024

CAS-No.:

202350-68-3

Go to product

Polybia- MP1 trifluoroacetate salt

Article number:

5600115

CAS-No.:

872043-01-1

Go to product

ADCs

Cfm Oskar Tropitzsch GmbH supplies unique molecules - in this case the cytotoxins for antibodies. These payloads are ultra-toxic drugs, i.e. cytotoxic and/or cytostatic molecules, effective at a low dosage and therefore classified as highly potent APIs (HPAPIs). As usual we supply unique niche molecules which might become the next block buster molecules. Our focus is future-orientated. We supply µg’s for the first trials, mg for further research and g for commercial production.Antibody-drug conjugates (ADCs) combine the highly specific targeting capabilities of monoclonal antibodies with the cytotoxicity of small molecule anticancer drugs. By linking such a drug to an antibody, it is delivered exclusively to target cells. Binding of the antibody to the target cell induces internalization of the antibody together with the drug. This optimizes the efficacy of the cytotoxic drug and simultaneously minimizes its undesired side effects by avoiding uptake by non-affected cells. Some of these ADCs are already approved and dozens of promising ones are currently in clinical trials. Although most emphasis is currently put on cancer therapeutics, ADCs are as well suitable for optimized targeting of many other active components to affect cells and tissues. ADC technology offers a wide potential for the future. Many compounds that are already in pharmaceutically use, but also those that were postponed by now (either due to low efficacy or due to severe side effects), could be significantly improved by application in ADC technology.Besides the ADCs we provide you with our worldwide network capabilities – contact to linker technology companies, novel linker reagents or analytical services.Our portfolio consists of small molecules, large molecules, peptides and contract research based products as well of various inhibitors. We supply what you need to make your ADCs working!

Amanita Phalliodes